This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Memorial Sloan-Kettering Cancer Center
Drug Names(s): 8H9 MAb
Description: 8H9 MAb is a mouse IgG1 monoclonal antibody with specificity for the B7H3 antigen.
8H9 MAb was developed by the Memorial Sloan-Kettering Cancer Center.
Memorial Sloan-Kettering and United Therapeutics
In December 2007, United Therapeutics entered into an agreement with Memorial Sloan-Kettering Cancer Center to exclusively license certain rights to 8H9 antibody for the treatment of metastatic brain cancer. No terms were disclosed.
In July 2013, United Therapeutics announced that they have elected to discontinue their involvement in the program and therefore have terminated the license agreement with Sloan-Kettering Institute for Cancer Research. The termination is effective September 30, 2013.
8H9 MAb News
Pink Sheet FDA Performance Tracker: User Fee Goal Dates
Additional information available to subscribers only: